The Austin-based medicine company, Lumos Pharma, has just been awarded with $5.5 million by Wellcome Trust. Based on previous reports, it has completed $14 million on its Series A round of funding earlier this year from two companies, namely New Enterprise Associates and Sante Ventures.
The total of $19.5 million funds will be used by the company to further its development on finding treatment for Creatine Transporter Deficiency (CTD). CTD is a medical condition for boys that usually caused speech defects and seizures. CTD has been overlooked by most of the biotech community as it was often misdiagnosed as autism.
Read more about this story here